

Korean travelers' knowledge, attitude and practices on prevention of imported infectious diseases

¹연세대학교 의과대학 신촌세브란스병원 감염내과, ²성균관대학교 의과대학 삼성서울병원 소아청소년과, ³성균관대학교 의과대학 강북서울병원 감염내과, ⁴서울대학교 분당서울대학교병원 감염내과, ⁵가톨릭대학교 서울성모병원 국제진료센터

*이운지¹, 김예진², 주은정³, 김의석⁴, 옥진주⁵, 염준섭¹

Background/Aims: Korean travelers going abroad are increasing every year. Imported infectious diseases also have increased because of migration of people, global warming and urbanization. **Methods:** Two questionnaires originally developed by European Travel Health Advisor Board for survey of knowledge, attitude and practice of pre-travel vaccination and malaria chemoprophylaxis were modified and translated into Korean with permission before use. Questionnaires were distributed to total 1,641 travelers from August to November in 2015, in three different travel clinics, quarantine offices, and the Incheon International Airport. **Results:** Of 1641 travelers, male was 874(53.2%) and female was 767(46.8%). Mean age was 39.4 years old. Destination of respondents was diverse, including about 60 countries. The purpose of travel was mostly tourism (50.5%), business (26.6%) and volunteer/missionary (12.5%). Duration of travel was within 7days for 48.3%, 8 to 14 days for 22.3%, and more than 29 days for 20.6%. Characteristics of travelers going to countries with high-to-middle risk of acquiring malaria were compared with travelers going to low malaria risk countries. They were predominantly male (348, 67.9%), tourist (246, 43.8%) traveling for longer duration and seek more pre-travel health advice (459, 81.7%) compared to malaria low risk group. Among travelers going to high malaria risk areas, shorter duration of trip (OR 2.84, $p<0.001$) and volunteers or missionary workers (OR 0.11, $p<0.001$) were significant factors for not seeking pre-travel health advice before departure. Travelers going to malaria high risk area used mosquito repellent only 27.2%, chemoprophylaxis 21.7%. Many travelers decided not to take malaria chemoprophylaxis because they don't like taking any kind of medicine (30.3%), doubts about efficacy of drugs (10.2%) and high cost of prophylactic drugs (8.0%). **Conclusions:** Health information seeking behavior and health risk assessment by most Korean traveler are still in many ways inappropriate. Providing recommended vaccines and chemoprophylaxis with exact health information for travelers by travel medicine experts is needed.

Purpose	Preparing duration (days)				Total
	1~7 (%)	8~14 (%)	15~28 (%)	>29 (%)	
Business	165 43.3	100 38.0	78 29.2	74 10.9	417
Tourism	165 43.3	125 47.5	141 52.8	380 55.8	811
Volunteer/Missionary	13 3.4	20 7.6	31 11.6	141 20.7	205
Education	15 3.9	10 3.8	8 3.0	15 2.2	48
Friends/Relatives	13 3.4	3 1.1	9 3.4	21 3.1	46
Sports	8 2.1	2 0.8	1 0.4	13 1.9	24
Others	7 1.8	5 1.9	5 1.9	43 6.3	60
Total	386	265	273	687	1611

	Male	Female	Total
Number of travelers getting information before trip (allowing multiple answers)	600 (53.7%)	517 (46.3%)	1117
Source			
Internet	473	413	951 (85.1%)
Friends/Relatives/Natives	175	143	233 (20.9%)
Call service (quarantines etc.)	26	30	22 (2.0%)
Cellphone applications	26	36	42 (3.8%)
Traveling books/Journals	70	82	102 (9.1%)

Chemoprophylactic drugs	Low risk area (n=280)	High risk area (n=240)
Malarone (Atovaquone/proguanil)	38(13.6%)	58(24.2%)
Lariam (mefloquine)	23(8.2%)	33(13.8%)
Chloroquine	19(6.8%)	4(1.7%)
Doxycycline	23(8.2%)	9(3.7%)
Do not know what kind of drugs were prescribed	177(63.2%)	136(56.7%)

Comparison of characteristic between pneumococcal meningitis and pneumococcal bacteremic pneumonia

¹고려대학교 의과대학, ²조선대학교 의과대학, ³경상대학교 병원, ⁴충남대학교 의과대학, ⁵연세대학교 원주의과대학, ⁶제주한라병원, ⁷아주대학교 의과대학, ⁸가천대학교 길병원, ⁹대구가톨릭대학교 의과대학, ¹⁰충북대학교 의과대학, ¹¹삼육의료원, ¹²영남대학교 병원

*김정연¹, 김종훈¹, 김동민², 배인규³, 김연숙⁴, 김효율⁵, 백승희⁶, 최영희⁷, 조유미⁸, 송준영⁹, 권현희¹⁰, 정혜원¹¹, 김정은¹², 허지안¹², 김선민¹, 윤영경¹, 손장욱¹, 김민지¹

Background/Aims: Pneumococcal meningitis (PM) is one of invasive pneumococcal disease (IPD) and is considered as a medical emergency with notable morbidity and mortality. This study was designed to characterize differences in clinical characteristics and outcomes, pneumococcal serotypes, and antimicrobial susceptibilities between PM and pneumococcal bacteremic pneumonia (BPB) in adult patients in the Republic of Korea (ROK) from a prospective observational cohort. **Methods:** Adult IPD cases (≥ 18 years) were prospectively collected from 20 hospitals participated in the pneumococcal surveillance program in the ROK from 2013 through 2015. Serotyping and antimicrobial susceptibility testing were performed by a multiplexed serotyping assay and Microscan system, respectively. **Results:** During the study period, 30 cases of PM and 205 cases of BPB were compared. Serotypes 19A, 15B/15C, and 35B were the most prevalent among PM cases, whereas serotypes 3, 11A/D/F, and 19A were the most common serotypes in BPB. There were significant female predominance (46.7% vs 2.3%, $p=0.022$), younger age (56.7% vs 36.1%, $p=0.031$), less immunocompromised states (3.3% vs 28.8%, $p=0.005$), less underlying chronic lung diseases (3.3% vs 16.6%, $p=0.04$), and lower mortality rate (16.7% vs 44.4%, $p=0.004$) in PM, compared to BPB. However, PM cases showed higher penicillin resistance (76.7% vs 19.2%, $p<0.001$), and ceftriaxone resistance (53.3% vs 13.4%, $p<0.001$), consistent with higher MDR prevalence in PM cases (76.7% vs 53.2 $P=0.016$). All PM cases except for 3 cases received empiric or definite vancomycin treatment. Multiple logistic regression analysis showed that penicillin resistance (odds ratio [OR] 15.75, 95% confidence interval (CI) 3.82-64.72, $p<0.001$) and survival (OR 20.73, 95% CI 3.1-136.74, $p=0.002$) were significantly associated with PM. **Conclusions:** This study indicates that adult PM showed favorable clinical outcomes, compared to BPB, despite of differences in clinical characteristics.

	Bacteremic Pneumonia	Meningitis	p
Male, n (%)	151 (73.7)	16 (53.3)	
Female, n (%)	54 (2.3)	14 (46.7)	0.022
Age			
>= 65 years, n (%)	131 (63.9)	13 (43.3)	0.031
Mean	68.2 ± 13.0	62 ± 13.8	
Median	70 (IQR 58-78)	62 (IQR 54-72)	0.019
Immunocompromised			
IC w/ Chronic	22 (10.7)	0 (0.0)	0.087
IC w/o Chronic	33 (16.1)	1 (3.3)	0.091
IC w/o C	95 (28.8)	1 (3.3)	0.005
Underlying disease			
만성심장질환	24(11.7)	1(3.3)	0.138
만성폐질환	54(26.6)	1(3.3)	0.04
만성간질환	18(8.8)	1(3.3)	0.27
만성신부전	11(5.4)	0(0.0)	0.215
만성신경질환	28(13.7)	2(6.7)	0.225
CSF 누출	0(0.0)	1(3.3)	0.128
당뇨병	41(20.0)	4(13.3)	0.386
요양기관거주	48(23.4)	3(10.0)	0.096
흡연	11(5.4)	0(0.0)	0.531
알코올 중독	11(5.4)	0(0.0)	0.215
병명 전 예방접종			
PPV 23	45(22.0)	6(20.0)	1
PCV 13	1(0.5)	0(0.0)	
Both PPV23 PCV13	0(0.0)	1(3.3)	

	Bacteremic Pneumonia	Meningitis	p
Serotype			
Serotype available	121	19	
Noncapsule	31	7	0.306
PPV23	90	12	0.687
PCV13	52	5	0.299
PCV 13 or PPV23 covered serotypes	90(74.4)	12(63.2)	0.306
Susceptibility			
Penicillin SUS	164(80.8)	7(23.3)	0
Ceftriaxone SUS	161(86.6)	14(46.7)	0
Vancomycin SUS	202(100)	30(100)	NA
Levofloxacin SUS	195(95.1)	29(96.7)	0.578
Mecopenem SUS	174(86.1)	6(26.1)	0.082
Clindamycin SUS	94(47.2)	10(33.3)	0.154
TMX-SUS SUS	112(59.6)	11(42.3)	0.095
Erythromycin SUS	56(27.8)	4(13.3)	0.101
MDR streptococcus	106(53.2)	23(76.7)	0.016
PBS score			
Mean	3.2 ± 2.6	2.3 ± 1.4	0.902
Median	2 (IQR 0-5)	2 (IQR 1.00 ~ 3.75)	
PTT bacteremia score >=4	8(40.5)	6(25.0)	0.141
Initial discordant tx	1(5.7)	4(17.4)	0.277
Mortality	9(44.4)	5(16.7)	0.004
입원기간			
Mean	9.5 ± 20.8	32 ± 27.4	0.902
Median	3 (IQR 1-11)	23 (IQR 10.5 ~ 58)	